U.K.'s Cost Effectiveness Watchdog Backs Novo Nordisk's Victoza

NICE recommends Novo Nordisk's diabetes therapy Victoza, but only at one dose and as an alternative to other therapies.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet